Additionally, inhibition kinetics of exogenously added APC, APC inhibitor levels, and APC sensitivity ratios were measured in plasma. Expression of TM (thrombomodulin) and EPCR (endothelial protein C ...

Researchers identified a key protein as a potential therapeutic target for stopping the body's immune system from mistakenly attacking itself, offering new hope for treating autoimmune diseases and ...

Houston Methodist researchers have identified a key protein as a potential therapeutic target for stopping the body's immune ...

Deciphera Pharmaceuticals LLC has patented new serine/threonine-protein kinase B-raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) inhibitors reported to be useful for ...

[5] Decreases in protein C and inhibition of the protein C system play important roles in the development of sepsis-associated coagulopathy. The importance of the protein C system in patients with ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Windtree Therapeutics (WINT) announced the issuance of a patent in Japan for “Inhibitors of atypical protein kinase C and their use in treating ...

(“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the ...